Measuring the concerns of cancer patients with low platelet counts: The Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th) questionnaire

David Cella*, Jennifer L. Beaumont, Kimberly A Webster, Jin-Shei Lai, Linda Elting

*Corresponding author for this work

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: The specific concerns of people with low platelet counts (thrombocytopenia) have not been characterized well in the literature and as a result proper measurement of patient-reported concerns is lacking. We report on the development and validation of questions specifically targeted to patients with thrombocytopenia that can be added to the more general concerns in the Functional Assessment of Cancer Therapy-General. Materials and methods: An 18-item FACT-Thrombocytopenia Subscale (ThS) was rated and evaluated by thrombocytopenic patients at baseline during a validation study of 40 thrombocytopenic and 43 nonthrombocytopenic cancer patients. To evaluate responsiveness, patients completed a battery of self-report measures including the FACT-Th and were followed up for change in platelet count over 2 weeks. Results: All subscales and aggregated scores showed high internal consistency at initial assessment and at retesting. Convergent and divergent validity were demonstrated by predicted relationships between FACT-Th subscales and mood, mental and physical component scores of the SF-36, and social desirability. The ThS differentiated patients with low platelets from those with normal platelet counts and good performance from poor performance status patients. Conclusion: The FACT-Th is a reliable and valid measure for assessing the impact of thrombocytopenia on patients' lives. It can distinguish cancer patients with and without thrombocytopenia and is responsive to increase in platelet count over time. The FACT-Th may therefore prove useful as a measure of self-reported symptoms and concerns related to thrombocytopenia in clinical trials evaluating new pharmacologic agents and/or platelet transfusion practice.

Original languageEnglish (US)
Pages (from-to)1220-1231
Number of pages12
JournalSupportive Care in Cancer
Volume14
Issue number12
DOIs
StatePublished - Dec 1 2006

Fingerprint

Platelet Count
Thrombocytopenia
Neoplasms
Therapeutics
Surveys and Questionnaires
Social Desirability
Platelet Transfusion
Validation Studies
Self Report
Blood Platelets
Clinical Trials

Keywords

  • FACT
  • Patient-reported outcome
  • Platelets
  • Quality of life
  • Thrombocytopenia

ASJC Scopus subject areas

  • Oncology

Cite this

@article{5c6523fd72594ad9adf73d8b5f32d563,
title = "Measuring the concerns of cancer patients with low platelet counts: The Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th) questionnaire",
abstract = "Purpose: The specific concerns of people with low platelet counts (thrombocytopenia) have not been characterized well in the literature and as a result proper measurement of patient-reported concerns is lacking. We report on the development and validation of questions specifically targeted to patients with thrombocytopenia that can be added to the more general concerns in the Functional Assessment of Cancer Therapy-General. Materials and methods: An 18-item FACT-Thrombocytopenia Subscale (ThS) was rated and evaluated by thrombocytopenic patients at baseline during a validation study of 40 thrombocytopenic and 43 nonthrombocytopenic cancer patients. To evaluate responsiveness, patients completed a battery of self-report measures including the FACT-Th and were followed up for change in platelet count over 2 weeks. Results: All subscales and aggregated scores showed high internal consistency at initial assessment and at retesting. Convergent and divergent validity were demonstrated by predicted relationships between FACT-Th subscales and mood, mental and physical component scores of the SF-36, and social desirability. The ThS differentiated patients with low platelets from those with normal platelet counts and good performance from poor performance status patients. Conclusion: The FACT-Th is a reliable and valid measure for assessing the impact of thrombocytopenia on patients' lives. It can distinguish cancer patients with and without thrombocytopenia and is responsive to increase in platelet count over time. The FACT-Th may therefore prove useful as a measure of self-reported symptoms and concerns related to thrombocytopenia in clinical trials evaluating new pharmacologic agents and/or platelet transfusion practice.",
keywords = "FACT, Patient-reported outcome, Platelets, Quality of life, Thrombocytopenia",
author = "David Cella and Beaumont, {Jennifer L.} and Webster, {Kimberly A} and Jin-Shei Lai and Linda Elting",
year = "2006",
month = "12",
day = "1",
doi = "10.1007/s00520-006-0102-1",
language = "English (US)",
volume = "14",
pages = "1220--1231",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Measuring the concerns of cancer patients with low platelet counts

T2 - The Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th) questionnaire

AU - Cella, David

AU - Beaumont, Jennifer L.

AU - Webster, Kimberly A

AU - Lai, Jin-Shei

AU - Elting, Linda

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Purpose: The specific concerns of people with low platelet counts (thrombocytopenia) have not been characterized well in the literature and as a result proper measurement of patient-reported concerns is lacking. We report on the development and validation of questions specifically targeted to patients with thrombocytopenia that can be added to the more general concerns in the Functional Assessment of Cancer Therapy-General. Materials and methods: An 18-item FACT-Thrombocytopenia Subscale (ThS) was rated and evaluated by thrombocytopenic patients at baseline during a validation study of 40 thrombocytopenic and 43 nonthrombocytopenic cancer patients. To evaluate responsiveness, patients completed a battery of self-report measures including the FACT-Th and were followed up for change in platelet count over 2 weeks. Results: All subscales and aggregated scores showed high internal consistency at initial assessment and at retesting. Convergent and divergent validity were demonstrated by predicted relationships between FACT-Th subscales and mood, mental and physical component scores of the SF-36, and social desirability. The ThS differentiated patients with low platelets from those with normal platelet counts and good performance from poor performance status patients. Conclusion: The FACT-Th is a reliable and valid measure for assessing the impact of thrombocytopenia on patients' lives. It can distinguish cancer patients with and without thrombocytopenia and is responsive to increase in platelet count over time. The FACT-Th may therefore prove useful as a measure of self-reported symptoms and concerns related to thrombocytopenia in clinical trials evaluating new pharmacologic agents and/or platelet transfusion practice.

AB - Purpose: The specific concerns of people with low platelet counts (thrombocytopenia) have not been characterized well in the literature and as a result proper measurement of patient-reported concerns is lacking. We report on the development and validation of questions specifically targeted to patients with thrombocytopenia that can be added to the more general concerns in the Functional Assessment of Cancer Therapy-General. Materials and methods: An 18-item FACT-Thrombocytopenia Subscale (ThS) was rated and evaluated by thrombocytopenic patients at baseline during a validation study of 40 thrombocytopenic and 43 nonthrombocytopenic cancer patients. To evaluate responsiveness, patients completed a battery of self-report measures including the FACT-Th and were followed up for change in platelet count over 2 weeks. Results: All subscales and aggregated scores showed high internal consistency at initial assessment and at retesting. Convergent and divergent validity were demonstrated by predicted relationships between FACT-Th subscales and mood, mental and physical component scores of the SF-36, and social desirability. The ThS differentiated patients with low platelets from those with normal platelet counts and good performance from poor performance status patients. Conclusion: The FACT-Th is a reliable and valid measure for assessing the impact of thrombocytopenia on patients' lives. It can distinguish cancer patients with and without thrombocytopenia and is responsive to increase in platelet count over time. The FACT-Th may therefore prove useful as a measure of self-reported symptoms and concerns related to thrombocytopenia in clinical trials evaluating new pharmacologic agents and/or platelet transfusion practice.

KW - FACT

KW - Patient-reported outcome

KW - Platelets

KW - Quality of life

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=33751265244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751265244&partnerID=8YFLogxK

U2 - 10.1007/s00520-006-0102-1

DO - 10.1007/s00520-006-0102-1

M3 - Article

C2 - 16944221

AN - SCOPUS:33751265244

VL - 14

SP - 1220

EP - 1231

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 12

ER -